TRICAN: The role of Tregs in the immune response to cancer (Q2907060): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: co-financing rate (P837): 85.0 percentage) |
(Changed an Item: Import item from Portugal) |
||||||||||
Property / budget | Property / budget | ||||||||||
| 239,909.8 Euro
| ||||||||||
Property / EU contribution | Property / EU contribution | ||||||||||
| 203,923.33 Euro
| ||||||||||
Property / priority axis | |||||||||||
Property / priority axis: Strengthening research, technological development and innovation (OT1) / rank | |||||||||||
Normal rank | |||||||||||
Property / co-financing rate | |||||||||||
85.0 percent
| |||||||||||
Property / co-financing rate: 85.0 percent / rank | |||||||||||
Normal rank |
Revision as of 02:11, 5 November 2022
Project Q2907060 in Portugal
Language | Label | Description | Also known as |
---|---|---|---|
English | TRICAN: The role of Tregs in the immune response to cancer |
Project Q2907060 in Portugal |
Statements
203,923.33 Euro
0 references
239,909.8 Euro
0 references
85.0 percent
0 references
26 July 2018
0 references
25 July 2021
0 references
IPATIMUP-INSTITUTO DE PATOLOGIA E IMUNOLOGIA MOLECULAR DA UNIVERSIDADE DO PORTO
0 references
Q2993205 (Deleted Item)
0 references
Porto
0 references
Identifiers
POCI-01-0145-FEDER-032462
0 references